Solvay had a very good start, reporting adjusted (!) EBITDA above pre-crisis levels. In the light of reality, the ugly scratches of the portfolio measures obviously weighed on profitability. Nevertheless, we are a bit more optimistic for the company, not just because our estimates were beaten by +5% (sales) and by +10% on the adjusted EBITDA (consensus: +2% and +11%), but the company beat its own estimates by +9%.
05 May 2021
Beating oneself – on an adjusted basis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Beating oneself – on an adjusted basis
- Published:
05 May 2021 -
Author:
Martin Schnee -
Pages:
3
Solvay had a very good start, reporting adjusted (!) EBITDA above pre-crisis levels. In the light of reality, the ugly scratches of the portfolio measures obviously weighed on profitability. Nevertheless, we are a bit more optimistic for the company, not just because our estimates were beaten by +5% (sales) and by +10% on the adjusted EBITDA (consensus: +2% and +11%), but the company beat its own estimates by +9%.